The Receptor Type Tyrosine Protein Kinase FLT3 pipeline drugs market research report outlays comprehensive information on the Receptor Type Tyrosine Protein Kinase FLT3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Receptor Type Tyrosine Protein Kinase FLT3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Genetic Disorders, and Undisclosed which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Idiopathic Pulmonary Fibrosis, Interstitial Lung Fibrosis, Familial Adenomatous Polyposis, Neurofibromatoses Type II, and Unspecified. It also reviews key players involved in Receptor Type Tyrosine Protein Kinase FLT3 targeted therapeutics development with respective active and dormant or discontinued products.
The Receptor Type Tyrosine Protein Kinase FLT3 pipeline targets constitutes close to 111 molecules. Out of which, approximately 98 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 2, 7, 21, 17, 4, 35, and 8 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 7 molecule.
Receptor Type Tyrosine Protein Kinase FLT3 overview
Receptor type tyrosine protein kinase FLT3 (FLT3) is a protein that plays a critical role in the regulation of hematopoiesis, the process of blood cell formation. FLT3 is a member of the class III receptor tyrosine kinase (RTK) family, and it is expressed on the surface of hematopoietic progenitor cells. When FLT3 is bound to its ligand, FLT3 ligand (FLT3L), it becomes activated and triggers a signaling cascade that promotes the proliferation and survival of hematopoietic cells.
For a complete picture of Receptor Type Tyrosine Protein Kinase FLT3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
